
Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

ADC company Araris Biotech raises CHF15.2m
Besides Pureos Bioventures, London-based 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq cofinanced the CHF12.7m addition to...

1,800+ experts will join the Global Bioeconomy Summit
First editions of the summit took place in Berlin in 2015 and 2018, this year it will be delivery fully virtually. The digital conference event...

Immunocore bags US$75m in Series C round
The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

Angelini Pharma to take over Arvelle Therapeutics
Under the terms of the agreement, Angelini Pharma will acquire Arvelle Therapeutics in an all-cash transaction for a total consideration of up to...

BioNTech reports high efficacy of COVID-19 vaccine
BioNTech/Pfizer are the first COVID-19 vaccine developers who provided the definitive proof-of-concept that it is possible to protect people from an...